RVNC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RVNC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate is 23.57.
For the Biotechnology subindustry, Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate falls into.
Revance Therapeutics (NAS:RVNC) Future 3-5Y Total Revenue Growth Rate Explanation
Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Revance Therapeutics's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Dwight Moxie | officer: SVP, GC & Secretary | 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Dustin S Sjuts | officer: President | 7555 GATEWAY BLVD, NEWARK CA 94560 |
Tobin Schilke | officer: Chief Financial Officer | 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080 |
Mark J Foley | director | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Carey Oconnor Kolaja | director | C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203 |
Vlad Coric | director | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Aubrey Rankin | director | C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560 |
Angus C. Russell | director | C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Olivia C Ware | director | 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049 |
Chris Nolet | director | C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Jill Beraud | director | C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111 |
L Daniel Browne | director, officer: CEO and President | 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Cyril Allouche | officer: Principal Financial Officer | 7555 GATEWAY BLVD., NEWARK CA 94560 |
Lauren P Silvernail | officer: CFO, Seretary & EVP Corp Dev. | 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618 |
Caryn Gordon Mcdowell | officer: SVP, GC & Secretary | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PRNewswire • 10-03-2024
By PRNewswire • 10-01-2024
By PRNewswire • 11-02-2024
By Business Wire • 11-07-2024
By PRNewswire • 10-17-2024
By Business Wire • 08-12-2024
By PRNewswire • 09-27-2024
By PRNewswire • 08-12-2024
By Marketwired • 08-12-2024
By PRNewswire • 10-25-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.